Avantor, Inc. (NYSE:AVTR) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. decreased its holdings in shares of Avantor, Inc. (NYSE:AVTR) by 28.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 95,674 shares of the company’s stock after selling 37,841 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Avantor were worth $2,475,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of AVTR. Versant Capital Management Inc grew its holdings in shares of Avantor by 2,003.6% in the second quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock valued at $25,000 after purchasing an additional 1,102 shares during the period. Blue Trust Inc. grew its holdings in shares of Avantor by 1,830.3% in the second quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock valued at $31,000 after purchasing an additional 1,391 shares during the period. UMB Bank n.a. purchased a new stake in shares of Avantor in the third quarter valued at about $49,000. GAMMA Investing LLC grew its holdings in shares of Avantor by 89.9% in the third quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock valued at $70,000 after purchasing an additional 1,285 shares during the period. Finally, Livforsakringsbolaget Skandia Omsesidigt grew its holdings in shares of Avantor by 278.0% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 5,031 shares of the company’s stock valued at $130,000 after purchasing an additional 3,700 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on AVTR. Morgan Stanley upped their price objective on shares of Avantor from $28.00 to $29.00 and gave the company an “overweight” rating in a report on Monday, July 29th. Barclays lowered their target price on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research note on Friday, October 25th. Robert W. Baird lowered their target price on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research note on Monday. Stifel Nicolaus increased their target price on shares of Avantor from $27.00 to $28.00 and gave the stock a “buy” rating in a research note on Monday, July 29th. Finally, Wells Fargo & Company lowered their target price on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, Avantor presently has an average rating of “Moderate Buy” and a consensus target price of $27.57.

Insider Activity at Avantor

In related news, CAO Steven W. Eck sold 3,525 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $25.06, for a total value of $88,336.50. Following the sale, the chief accounting officer now owns 29,544 shares of the company’s stock, valued at $740,372.64. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.50% of the stock is owned by corporate insiders.

Avantor Stock Down 0.4 %

Shares of AVTR opened at $22.37 on Friday. The company’s 50-day simple moving average is $25.26 and its 200-day simple moving average is $24.19. The stock has a market capitalization of $15.20 billion, a PE ratio of 57.36, a P/E/G ratio of 2.93 and a beta of 1.33. Avantor, Inc. has a 1 year low of $17.06 and a 1 year high of $28.00. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.05 and a current ratio of 1.59.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.